All In Biotech

Drug Trial Radar · NCT06483555

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Feb 6, 2025

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe, tolerable, and helpful for people with advanced pancreatic cancer. All participants are first tested with a tool called PurIST, which classifies tumors as either "basal-like" or "classical." People with basal-like tumors will receive GnP plus erlotinib during Phase I so researchers can determine the safest and most effective dose. Once that dose is identified, the study moves to Phase II, where people with basal-like tumors will be randomly assigned to receive either GnP alone or GnP with erlotinib. Phase II may also test new drug combinations if new treatments become approved during the study period. Overall, the trial plans to include up to about 52 basal-like patients in Phase I, roughly 82 basal-like patients in Phase II, and at least 52 classical patients, with the possibility of enrolling more if needed. People whose tumors are classified as classical will continue with standard treatments recommended by their doctors or other clinical trials. Across the entire study, researchers will carefully track long-term outcomes such as overall survival, how long patients live before the cancer progresses, and how well their tumors respond to treatment.

Conditions

  • Pancreatic Adenocarcinoma
  • Metastatic Pancreatic Cancer
  • Basal Cell Neoplasm

Interventions

  • GemcitabineDrug

    1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.

  • Nab paclitaxelDrug

    125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.

  • ErlotinibDrug

    50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.

  • NALIRIFOXDrug

    Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.

  • FolfirinoxDrug

    Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE)Time frame: First day of study treatment through the 28 days after last treatment
  2. Dose-limiting toxicity (DLT)Time frame: Up to 28 days
  3. Overall survival- classical metastatic pancreatic adenocarcinomaTime frame: 2 years
  4. Progression-free survivalTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.